Program Header

SLAS2019 Short Courses

3D Cell-Based Assays for Drug De-Risking

Cell-based in vitro assays are used throughout the drug discovery and development chain, allowing for high throughput efficacy but also mechanistic-based toxicity testing. A big challenge however is the translation of in vitro assays towards the in vivo outcome. Physiological relevance is a key parameter to improve the predictive power of cell-based assays. The better we can reflect tissue architecture, composition and function the more predictive an in vitro assay will become. The 3D course covers advances in 3D cell culture technologies, assays and their use in drug discovery and development.

Who Should Attend:

Industry and academic scientists with mid- to advanced-level experience in cell-based assays or cell biology wishing to get a concise overview about technologies, advantages, cost and application examples of 3D cell-based assays.

How You Will Benefit From This Course:

  • Guidelines how to develop 3D cell-based assays.
  • Guidelines how to use 3D models for phenotypic drug discovery.
  • State of the art overview about current methods in the rapidly evolving field of 3D cell-based assays.
  • Solid starting point for participants interested in introducing 3D cell-based assays in their organization.
  • Gaining expertise to use advanced cell culture models for drug discovery and drug development

Course Topics:

  • In-depth overview of 3D cell culture technologies and models: Comparison of the most important methods for 3D cell culture including hydrogel, scaffold, self-assembly, bioprinting and multi-organ devices; implementation strategies, automation, and work flows; comparison of advantages, disadvantages and cost.
  • How to adapt assays and readouts for 3D cell culture models: Using and optimizing existing biochemical assays; applying imaging technology for growth-curve measurements; histology and immune histochemistry; high-content analysis.
  • Case studies for the use of 3D models in drug discovery: 3D tumor models; co-culture systems; applications in screening of large libraries; target validation, 3D-based phenotypic drug discovery
  • Case studies for the use of 3D and multi-organ models in development: Toxicology-related models derived either from primary cell sources or stem cells and their use for safety testing such as liver toxicology, inflammation-mediated toxicology.

Instructors:

James Evans

James Evans
Phenovista

Dr Evans earned his PhD from the University of Edinburgh working on LH and FSH secretion pathway kinetics in the lab of Prof Alan McNeilly at the Medical Research Council's Centre for Reproductive Health. After graduating, Dr Evans joined the Matsudaira lab at the Whitehead Institute where he worked on 3D kinetics of cytoskeletal structures in macrophages. He later became a Computational & Systems Biology Research Scientist at the Massachusetts Institute of Technology. After leaving academia, Dr Evans consulted for several drug discovery and technology companies before becoming part of the EPA's ToxCAST screening initiative in 2011. Dr Evans co-founded Phenovista Biosciences in 2014, a niche CRO that provides state-of-the-art, custom phenotypic assay services to biotech and pharma clients.

Olivier Frey

Olivier Frey
InSphero AG

Olivier Frey leads the Technology and Platforms group at InSphero AG, Switzerland. Before joining InSphero, he was group leader at the Department of Biosystems Science and Engineering of ETH Zurich, Switzerland. In the Bio Engineering Laboratory of Prof. Andreas Hierlemann he was responsible for the development of integrated microfluidic systems for single cell handling and 3D tissue cultures. Included are in particular multi-tissue systems, or so-called “Body-on-a-Chip” configurations based on 3D microtissue spheroids for microtissue culturing, analysis and interaction. Olivier Frey received his Doctoral degree in Micro Engineering from EPF Lausanne, Switzerland, Laboratory of Prof. Nico de Rooij.

Alex Ng

Alex Ng
Harvard Medical School / Harvard University

Alex Ng is a Systems Biology PhD student in Dr. George Church’s laboratory at Harvard Medical School. His research focuses on technologies to genetically engineer human tissues and cells, and uses next generation sequencing for systems-level characterization. He and his team constructed the first comprehensive human transcription factor library for stem cell differentiation and tissue engineering.

Patrick Guye

Patrick Guye
InSphero AG

Dr. Patrick Guye the chief scientific officer at InSphero. Previously, he held positions in industry (Sanofi) and academia (Massachusetts Institute of Technology, Princeton University) with focus on cell therapy, 3D cellular models/organoids, synthetic biology, human stem cell engineering, biologics and small molecules development, as well as precision genomic engineering. Patrick received his PhD in Molecular Infection Biology from the University of Basel.

Terry Riss

Terry Riss
Promega Corporation

Dr. Terry Riss started the Cell Biology program at Promega in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Manager, Cell Health involved in outreach educational training activities. Dr. Riss has participated in several NIH study sections reviewing HTS grants and is co-editor of the In Vitro Cell Based Assays section of the Assay Guidance Manual hosted by NIH.


Our Sponsors

Premier Sponsor:
Hamilton

  • Diamond Sponsor

    Artel
  • Diamond Sponsor

    BMG Labtech
  • Diamond Sponsor

    Corning
  • Diamond Sponsor

    Scinomix
  • Diamond Sponsor

    Thermo Fisher Scientific
  • Diamond Sponsor

    Waters
  • Platinum Sponsor

    Beckman Coulter
  • Platinum Sponsor

    Hamamatsu
  • Platinum Sponsor

    Miltenyi Biotec
  • Platinum Sponsor

    Molecular Devices
  • Platinum Sponsor

    Tecan
  • Gold Sponsor

    Agilent
  • Gold Sponsor

    Biotek
  • Gold Sponsor

    Eppendorf
  • Gold Sponsor

    Gilson
  • Gold Sponsor

    HighRes Biosolutions
  • Gold Sponsor

    Labcyte
  • Gold Sponsor

    StemoniX
  • Silver Sponsor

    Analytik Jena
  • Silver Sponsor

    BioNex Solutions
  • Silver Sponsor

    Cisbio
  • Silver Sponsor

    Greiner Bio-One
  • Silver Sponsor

    NanoTemper
  • Silver Sponsor

    Sirius Automation Group
  • Silver Sponsor

    Titian
  • Media Partner

    Biocompare
  • Media Partner

    Cell Press
  • Media Partner

    CLP
  • Media Partner

    DDN News
  • Media Partner

    DDW
  • Media Partner

    DTR
  • Media Partner

    GEN News
  • Media Partner

    Labcompare
  • Media Partner

    LabManager
  • Media Partner

    Science AAAS
  • Media Partner

    Select Science
  • Media Partner

    Technology Networks
  • Media Partner

    The Analytical Scientist
  • Media Partner

    The Scientist
  • Media Partner

    The Translational Scientist